Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors.

Barlesi F, Tomasini P.

Lancet Oncol. 2020 Apr 3. pii: S1470-2045(20)30207-2. doi: 10.1016/S1470-2045(20)30207-2. [Epub ahead of print] No abstract available.

PMID:
32251624
2.

Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report.

Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, Balleyguier C, Besse B, Marabelle A, Netzer F, Merad M, Robert C, Barlesi F, Gachot B, Stoclin A.

Ann Oncol. 2020 Apr 2. pii: S0923-7534(20)36387-0. doi: 10.1016/j.annonc.2020.03.300. [Epub ahead of print] No abstract available.

PMID:
32247642
3.

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.

Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV.

J Thorac Oncol. 2020 Mar 13. pii: S1556-0864(20)30198-2. doi: 10.1016/j.jtho.2020.03.006. [Epub ahead of print] Review.

PMID:
32179179
4.

Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.

Mazieres J, Barlesi F, Rouquette I, Molinier O, Besse B, Monnet I, Audigier-Valette C, Toffart AC, Renault PA, Fraboulet S, Hiret S, Mennecier B, Debieuvre D, Westeel V, Masson P, Madroszyk-Flandin A, Pichon E, Cortot AB, Amour E, Morin F, Zalcman G, Moro-Sibilot D, Souquet PJ.

Clin Cancer Res. 2020 Mar 6. pii: clincanres.3056.2019. doi: 10.1158/1078-0432.CCR-19-3056. [Epub ahead of print]

PMID:
32144133
5.

Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2.

Barlesi F, Drilon A, De Braud F, Cho BC, Ahn MJ, Siena S, Krebs MG, Lin CC, John T, Tan DSW, Seto T, Dziadziuszko R, Arkenau HT, Rolfo C, Wolf J, Ye C, Riehl T, Eng S, Doebele RC.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48-ii49. doi: 10.1093/annonc/mdz063.007. No abstract available.

6.

Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study.

Pérol M, Dixmier A, Barlesi F, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Moro-Sibilot D, Asselain B, Cotté FE, Lamoureux P, Karam N, Ozan N, Calvet C, Bryan B, Allan V, Audigier Valette C.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48. doi: 10.1093/annonc/mdz063.014. No abstract available.

7.

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations.

Reck M, Jotte R, Mok TSK, Lim DW, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Nishio M, Lee A, Shankar G, Yu W, Socinski MA.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48-ii49. doi: 10.1093/annonc/mdz063.002. No abstract available.

8.

Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice.

Sebastian M, Barlesi F, Califano R, Mansfield AS, Blackhall FH, Flahavan EM, Davies J, Arnold P, Morris S, Reck M.

Ann Oncol. 2019 Apr;30 Suppl 2:ii24. doi: 10.1093/annonc/mdz071.006. No abstract available.

9.

Illness representations and quality of life in French patients suffering from lung cancer.

Masson N, Dany L, Cannone P, Barlesi F, Baciuchka M, Tomasini P.

Psychol Health Med. 2020 Feb 17:1-11. doi: 10.1080/13548506.2020.1728349. [Epub ahead of print]

PMID:
32064908
10.

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

Mogenet A, Tomasini P, Greillier L, Barlesi F.

Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S383-S386. doi: 10.21037/tlcr.2019.05.10. No abstract available.

11.

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies.

Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SI.

Lung Cancer (Auckl). 2019 Nov 13;10:125-130. doi: 10.2147/LCTT.S209231. eCollection 2019.

12.

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.

Domblides C, Leroy K, Monnet I, Mazières J, Barlesi F, Gounant V, Baldacci S, Mennecier B, Toffart AC, Audigier-Valette C, Doucet L, Giroux-Leprieur E, Guisier F, Ricordel C, Molinier O, Perol M, Pichon E, Robinet G, Templement-Grangerat D, Ruppert AM, Rabbe N, Antoine M, Wislez M.

J Thorac Oncol. 2020 Jan 25. pii: S1556-0864(20)30054-X. doi: 10.1016/j.jtho.2020.01.014. [Epub ahead of print]

PMID:
31991225
13.

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.

Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY.

Ann Oncol. 2020 Feb;31(2):289-294. doi: 10.1016/j.annonc.2019.10.022. Epub 2020 Jan 3.

14.

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.

Beau-Faller M, Pencreach E, Leduc C, Blons H, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, Ouafik L, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Moro-Sibilot D, Barlesi F, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).

Lung Cancer. 2020 Feb;140:19-26. doi: 10.1016/j.lungcan.2019.10.013. Epub 2019 Nov 15.

PMID:
31841714
15.

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators.

Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Erratum in: Lancet Oncol. 2020 Feb;21(2):e70.

PMID:
31838015
16.

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN, Shaw AT.

Lung Cancer. 2020 Jan;139:22-27. doi: 10.1016/j.lungcan.2019.10.015. Epub 2019 Oct 14.

PMID:
31706099
17.

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

Bennouna J, Girard N, Audigier-Valette C, le Thuaut A, Gervais R, Masson P, Marcq M, Molinier O, Cortot A, Debieuvre D, Cadranel J, Lena H, Moro-Sibilot D, Chouaid C, Mennecier B, Urban T, Sagan C, Perrier L, Barlesi F, Denis MG.

Clin Lung Cancer. 2020 Jan;21(1):e10-e14. doi: 10.1016/j.cllc.2019.09.007. Epub 2019 Oct 1.

PMID:
31648999
18.

High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.

Baldacci S, Figeac M, Antoine M, Descarpentries C, Kherrouche Z, Jamme P, Copin MC, Tulasne D, Nanni I, Beau-Faller M, Melaabi S, Levallet G, Quoix E, Moro-Sibilot D, Friard S, Missy P, Barlesi F, Cadranel J, Cortot AB.

J Thorac Oncol. 2020 Jan;15(1):120-124. doi: 10.1016/j.jtho.2019.09.196. Epub 2019 Oct 9.

PMID:
31605799
19.

A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.

Besse B, Barlesi F, Demedts I, Fuentes Pradera J, Robinet G, Gazzah A, Soldatenkova V, Frimodt-Moller B, Kim JS, Vansteenkiste J.

Lung Cancer. 2019 Nov;137:136-143. doi: 10.1016/j.lungcan.2019.09.002. Epub 2019 Sep 3.

PMID:
31586771
20.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G.

Ann Oncol. 2019 Dec 1;30(12):1985-1991. doi: 10.1093/annonc/mdz407.

PMID:
31584608
21.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS.

N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.

PMID:
31562796
22.

Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France).

Heeke S, Benzaquen J, Hofman V, Ilié M, Allegra M, Long-Mira E, Lassalle S, Tanga V, Salacroup C, Bonnetaud C, Fayada J, Gazoppi L, Ribeyre L, Castelnau O, Garnier G, Cattet F, Nanni I, de Fraipont F, Cohen C, Berthet JP, Leroy S, Poudenx M, Marquette CH, Denis MG, Barlesi F, Hofman P.

Clin Lung Cancer. 2020 Jan;21(1):56-65.e8. doi: 10.1016/j.cllc.2019.07.010. Epub 2019 Aug 3.

PMID:
31519454
23.

Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer.

Bilous M, Serdjebi C, Boyer A, Tomasini P, Pouypoudat C, Barbolosi D, Barlesi F, Chomy F, Benzekry S.

Sci Rep. 2019 Sep 10;9(1):13018. doi: 10.1038/s41598-019-49407-3.

24.

Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess.

Ciccolini J, Barbolosi D, André N, Benzekry S, Barlesi F.

Ann Oncol. 2019 Nov 1;30(11):1690-1691. doi: 10.1093/annonc/mdz297. No abstract available.

PMID:
31504149
25.

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.

Pujol JL, Coffy A, Camerini A, Kotsakis A, Mencoboni M, Gusella M, Pasini F, Pezzuto A, Banna GL, Bilir C, Samantas E, Barlesi F, Roch B, Guillou A, Daurès JP.

PLoS One. 2019 Aug 20;14(8):e0220988. doi: 10.1371/journal.pone.0220988. eCollection 2019.

26.

First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.

Ackermann CJ, Reck M, Paz-Ares L, Barlesi F, Califano R.

Lung Cancer. 2019 Aug;134:245-253. doi: 10.1016/j.lungcan.2019.06.007. Epub 2019 Jun 19. Review.

PMID:
31319988
27.

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Léna H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D; Biomarkers France Contributors.

Eur J Cancer. 2019 Jul;116:86-97. doi: 10.1016/j.ejca.2019.04.016. Epub 2019 Jun 8.

PMID:
31181537
28.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 Aug 1;30(8):1321-1328. doi: 10.1093/annonc/mdz167.

PMID:
31125062
29.

Companion diagnostic tests for treatment of lung cancer patients: what are the current and future challenges?

Hofman P, Barlesi F.

Expert Rev Mol Diagn. 2019 May;19(5):429-438. doi: 10.1080/14737159.2019.1611426. Epub 2019 May 6.

PMID:
31018102
30.

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer.

Schneider BK, Boyer A, Ciccolini J, Barlesi F, Wang K, Benzekry S, Mochel JP.

CPT Pharmacometrics Syst Pharmacol. 2019 Aug;8(8):577-586. doi: 10.1002/psp4.12415. Epub 2019 May 9.

31.

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group.

Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.

PMID:
30922878
32.

Functional status in a geriatric oncology setting: A review.

Couderc AL, Boulahssass R, Nouguerède E, Gobin N, Guérin O, Villani P, Barlesi F, Paillaud E.

J Geriatr Oncol. 2019 Nov;10(6):884-894. doi: 10.1016/j.jgo.2019.02.004. Epub 2019 Feb 27. Review.

PMID:
30824222
33.

[Tumor banks and complex data management: Current and future challenges].

Hofman P, Dagher G, Laurent-Puig P, Marquette CH, Barlesi F, Bibeau F, Clément B.

Ann Pathol. 2019 Apr;39(2):137-143. doi: 10.1016/j.annpat.2019.01.017. Epub 2019 Feb 25. Review. French.

PMID:
30819623
34.

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu DR, Isla D, Barlesi F, Molinier O, Madelaine J, Audigier-Valette C, Kim SW, Kim HR, Ozguroglu M, Erman M, Badin FB, Mekhail TM, Scheff R, Chisamore MJ, Sadrolhefazi B, Riess JW.

Clin Lung Cancer. 2019 May;20(3):e407-e412. doi: 10.1016/j.cllc.2018.12.022. Epub 2019 Jan 4.

35.

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.

Tomasini P, Egea J, Souquet-Bressand M, Greillier L, Barlesi F.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619831906. doi: 10.1177/1753466619831906. Review.

36.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.

PMID:
30770348
37.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, Chaleat S, Khobta N, Milia J, Mhanna L, Greillier L, Biemar J, Nanni I, Ouafik L, Garcia S, Mazières J, Barlesi F, Mascaux C.

J Thorac Oncol. 2019 Jun;14(6):1095-1101. doi: 10.1016/j.jtho.2019.01.011. Epub 2019 Feb 6.

PMID:
30738221
38.

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.

Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G Jr, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS.

J Thorac Oncol. 2019 May;14(5):793-801. doi: 10.1016/j.jtho.2019.01.016. Epub 2019 Jan 31. Erratum in: J Thorac Oncol. 2019 Jul;14(7):1306.

PMID:
30711649
39.

Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.

Reck M, Horn L, Novello S, Barlesi F, Albert I, Juhász E, Kowalski D, Robinet G, Cadranel J, Bidoli P, Chung J, Fritsch A, Drews U, Wagner A, Govindan R.

J Thorac Oncol. 2019 Apr;14(4):701-711. doi: 10.1016/j.jtho.2019.01.010. Epub 2019 Jan 21. Erratum in: J Thorac Oncol. 2019 Aug;14(8):1484.

40.

Efficacy and safety of nivolumab in patients with non-small cell lung cancer: a retrospective study in clinical practice.

Montana M, Garcia ME, Ausias N, Jeanpierre M, Meiffren M, Giorgi R, Vanelle P, Barlesi F.

J Chemother. 2019 Apr;31(2):90-94. doi: 10.1080/1120009X.2018.1551753. Epub 2018 Dec 30.

PMID:
30595104
41.

"I think it's a bit early for now": impact of psychological factors on drafting advance directives among cancer patients.

Cannone P, Tomasini P, Paul M, Barlesi F, Dany L.

J Psychosoc Oncol. 2019 Jan-Feb;37(1):37-49. doi: 10.1080/07347332.2018.1541494. Epub 2018 Dec 26.

PMID:
30585529
42.

The clinical utility of tumor mutational burden in non-small cell lung cancer.

Greillier L, Tomasini P, Barlesi F.

Transl Lung Cancer Res. 2018 Dec;7(6):639-646. doi: 10.21037/tlcr.2018.10.08. Review.

43.

Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.

Jeanson A, Boyer A, Greillier L, Tomasini P, Barlesi F.

Expert Rev Anticancer Ther. 2019 Jan;19(1):11-17. doi: 10.1080/14737140.2019.1554440. Epub 2018 Dec 4. Review.

PMID:
30513023
44.

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.

Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, Boucekine M, Mascaux C, Barlesi F.

Clin Lung Cancer. 2019 May;20(3):201-207. doi: 10.1016/j.cllc.2018.10.002. Epub 2018 Oct 11.

PMID:
30442524
45.

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.

Patel JD, Paz-Ares L, Zinner RG, Barlesi F, Koustenis AG, Obasaju CK.

Clin Lung Cancer. 2018 Nov;19(6):e823-e830. doi: 10.1016/j.cllc.2018.05.013. Epub 2018 May 26. Review.

PMID:
30369427
46.

Specialists to the Rescue of Oncologists for the Management of Toxicity Occurring Under Combination of Anticancer Therapies.

Chevalier T, Burtey S, Barlesi F.

J Thorac Oncol. 2018 Nov;13(11):e231-e232. doi: 10.1016/j.jtho.2018.07.003. No abstract available.

47.

[Autoimmune-related bleeding occurring during combined immunotherapy for lung cancer - Case report].

Eberst G, Lakhzoum W, Tomasini P, Andreotti N, Abcaya J, Mascaux C, Barlesi F.

Rev Mal Respir. 2018 Nov;35(9):974-977. doi: 10.1016/j.rmr.2018.01.013. Epub 2018 Oct 11. French.

PMID:
30318433
48.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Ellers-Lenz B, Bajars M, Ruisi M, Park K.

Lancet Oncol. 2018 Nov;19(11):1468-1479. doi: 10.1016/S1470-2045(18)30673-9. Epub 2018 Sep 24. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30262187
49.

ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?

Cabillic F, Hofman P, Ilie M, Peled N, Hochmair M, Dietel M, Von Laffert M, Gosney JR, Lopez-Rios F, Erb G, Schalles U, Barlesi F.

ESMO Open. 2018 Sep 17;3(6):e000419. doi: 10.1136/esmoopen-2018-000419. eCollection 2018.

50.

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.

Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L.

J Thorac Oncol. 2018 Dec;13(12):1906-1918. doi: 10.1016/j.jtho.2018.08.2027. Epub 2018 Sep 11.

Supplemental Content

Loading ...
Support Center